Related Experiment Videos
[3H]QNB displays in vivo selectivity for the m2 subtype
M S Gitler1, R De la Cruz, B R Zeeberg
1Department of Radiology, George Washington University Medical Center, Washington, D.C.
Life Sciences
|January 1, 1994
Summary
[3H]QNB shows in vivo m2-selectivity for muscarinic acetylcholine receptors, aiding Alzheimer's disease research. This finding may lead to new PET imaging agents for studying receptor loss in Alzheimer's disease.
Area of Science:
- Neuroscience
- Radiochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) is associated with selective loss of muscarinic m2 neuroreceptors in the human brain.
- Studying m2 receptor loss in AD using emission tomography is hindered by the lack of a suitable blood-brain barrier-penetrating m2-selective radioligand.
- The commonly used [3H]QNB is not subtype-selective in in vitro studies.
Purpose of the Study:
- To investigate the in vivo subtype selectivity of [3H]QNB for muscarinic acetylcholine receptors (mAChRs).
- To evaluate the potential of radiolabeled QNB derivatives for in vivo imaging of m2 receptor loss in Alzheimer's disease.
Main Methods:
- In vivo studies using both carrier-free and low specific activity [3H]QNB.
- Comparison with previously reported in vivo binding data for (R,R)-[125I]IQNB.
Main Results:
- [3H]QNB demonstrated significant in vivo m2-selectivity.
- In contrast, previously reported in vivo (R,R)-[125I]IQNB binding was found to be non-subtype-selective.
- Bulky iodine substitution at the 4-position of QNB appears to reduce its subtype selectivity.
Conclusions:
- [3H]QNB exhibits useful in vivo m2-selectivity, offering a potential tool for Alzheimer's disease research.
- A radiolabeled QNB derivative, potentially with fluorine (18F) substitution, could be valuable for positron emission tomographic (PET) imaging of m2 receptor loss in AD.